Hiqa asks RTÉ for all nursing home documentary footage
RTÉ has said it will not hand over non-broadcast footage to The Health Information and Quality Authority (Hiqa) without a statutory obligation or legal order.
Hiqa said it has asked the national broadcaster to provide all footage it captured in the making of an RTÉ Investigates documentary into standards of care at two nursing homes.
Advertisement
The programme highlighted serious issues at two centres – The Residence Portlaoise and Beneavin Manor in Glasnevin, Dublin – which have been acknowledged as 'wholly unjustifiable' by Emeis Ireland.
Hiqa, which is responsible for inspecting nursing homes, said it had notified gardai about its concerns arising from the programme.
The authority's chief executive, Angela Fitzgerald, told the Health Committee on Wednesday: 'We've also asked RTÉ to give us all of the footage because they have, maybe, more information than we currently have.
'We also need to be able to see it, because we need to make sure that every resident, not just the ones that were on the screen, are safe.
Advertisement
'And they have agreed to cooperate with us and hopefully they will be able to provide the information we need.'
In her written submission to the same committee, Ms Fitzgerald said that RTÉ director general Kevin Bakhurst confirmed that the broadcaster 'will assist us in whatever way they can'.
Asked about the comments, a spokeswoman for RTÉ confirmed it was engaging with Hiqa – which is due to request a meeting with the documentary team.
However, she said: 'Any assistance provided by RTÉ will be referenced by our own guidelines, safeguards, protocols and procedures.
Advertisement
'RTÉ does not hand non-broadcast footage to third parties without a statutory obligation or legal order.'
She added: 'Hiqa have now confirmed they have referred incidents evidenced in the RTÉ programme to An Garda Síochána.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
US judge invalidates Biden rule protecting privacy for abortions
June 18 (Reuters) - A federal judge on Wednesday struck down a rule adopted by the administration of former President Joe Biden that strengthened privacy protections for women seeking abortions and patients who receive gender transition treatments. U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas, said the U.S. Department of Health and Human Services exceeded its powers and unlawfully limited states' ability to enforce their public health laws when it adopted the rule last year. The rule prohibits healthcare providers and insurers from giving information about a legal abortion to state law enforcement authorities who are seeking to punish someone in connection with that abortion. "HHS lacked clear delegated authority to fashion special protections for medical information produced by politically favored medical procedures," wrote Kacsmaryk, who was appointed by President Donald Trump, a Republican, during his first term. Kacsmaryk in December had blocked HHS from enforcing the rule against a Texas doctor who had brought the lawsuit, Carmen Purl, pending the outcome of the case. Wednesday's decision blocks the rule nationwide. HHS and Alliance Defending Freedom, a conservative Christian legal group that represents Purl, did not immediately respond to requests for comment. The Biden administration issued the rule as part of its pledge to support access to reproductive healthcare after the conservative-majority U.S. Supreme Court in 2022 overturned the 1973 Roe v. Wade ruling that made access to abortion a constitutional right nationwide. It came in response to efforts by authorities in some Republican-led states that ban abortion, including Texas, to restrict out-of-state travel for abortion. Texas has filed a separate lawsuit challenging the rule, which is pending in federal court in Lubbock, Texas. HHS in a court filing last month said agency leadership appointed by Trump is evaluating its position in this case. Biden, a Democrat, said in announcing the rule that no one should have their medical records "used against them, their doctor, or their loved one just because they sought or received lawful reproductive health care."
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE 'I've dreamed of this moment': First ever patient gets 'world's most expensive drug' on the NHS - it costs £2.6million per dose
A 44-year-old man has become the first ever patient to receive a life-changing dose of the 'world's most expensive drug' on the NHS. Called Hemgenix, the drug—which costs an estimated £2.6million per patient—was administered yesterday at St Thomas' NHS Foundation Trust in London. Delivered as a one-off IV drip, it is the only treatment of its kind for haemophilia B. This is a bleeding disorder where the body doesn't make enough—or any—of a vital protein critical to clotting. Clotting stops wounds from bleeding, so those with the disorder risk suffering severe and even life-threatening blood loss from even minor injuries. Patients also run the risk of what are called 'spontaneous bleeds', which can be triggered without a direct injury and even prove deadly if they occur in a vital organ. Prior to Hemgenix, all haemophilia B patients needed regular weekly injections of an artificial clotting agent to keep their risk of catastrophic injury to a minimum. The patient, speaking anonymously, was diagnosed with haemophilia B when he was just 18 months old, and said he was now looking forward to a life 'free of worry'. 'I've always had to be more cautious and to plan ahead. There is a level of anxiety in that and being overly cautious has often led to missed opportunities and things I can't do, like contact sports,' he told MailOnline. 'To experience a life free of the worry and to do things that I wouldn't normally do will also be amazing.' He added: 'Not needing to plan ahead for treatment deliveries or looking up hospitals in foreign destinations when going on holiday, or having to tell people "sorry I can't do that I've got haemophilia", will be something I've always dreamed of.' Medics and charities have hailed the roll-out of the therapy as a critical milestone for helping those with the condition lead more fulfilling lives. Dr Pu-Lin Luo, the consultant haematologist at Guy's and St Thomas' who administered the treatment yesterday said it represented an 'exciting' step in treating the condition. 'This is a big step forward in our ability to manage haemophilia B and could change the lives of some of our patients. 'It is also a testament to the advancement of cell and gene therapies in the UK,' she said. Kate Burt, chief executive of charity The Haemophilia Society, also added: 'Today marks an important milestone not just for this patient, but for all those living with haemophilia B in the UK.' 'The current treatment of lifelong intravenous injections can place a significant burden on those living with haemophilia and it has an impact on broader family, relationships and work. 'The availability of gene therapy for haemophilia B as a one-time infusion will allow those eligible for treatment to expand their horizons and live life to the full, free from the restrictions of regular injections.' Despite being approved for use on the NHS last year, yesterday's treatment is the first time Hemgenix has been used by the health service. It's also the first time the drug has been used in the UK outside of a clinical trial. Hemgenix is the brand name of the drug etranacogene dezaparvovec. It works by replacing a patient's defective gene—which is incapable of producing the clotting protein—with one that can, eliminating the need for regular injections. Studies on the gene therapy have shown the protective effect lasts for at least three years, but the hope is it could work for even longer. There are approximately 2,000 people with haemophilia B in the UK. Yet only around 260 with 'moderately severe or severe haemophilia B' are currently eligible for Hemgenix on the NHS. This puts the potential total bill to the taxpayer at about £676million. MailOnline understands, however, that the NHS acquired the drug at an undisclosed discount, so the actual cost is likely to be less. Additionally, while the cost of the drug is roughly £2.6million per patient, medics claim the treatment actually saves the NHS money in the long term. The lifetime cost of providing a patient the alternative weekly clotting injections has been estimated to be £8million. This sum doesn't include the cost of life-saving interventions and surgeries haemophilia B may also need. Hemgenix is made by Philadelphia-based pharmaceutical company CSL Behring. Reacting to the news today the firm's general manager for UK and Ireland, Eduardo Cabas, said: 'This patient receiving etranacogene dezaparvovec is a testament to the collaborative efforts of the haemophilia community, NICE and NHS England to ensure that patients in the UK are able to access this one-time treatment option.' Hemgenix was initially described as the 'most expensive drug in the world' when it originally came onto the scene in 2022. However, other drugs—also gene therapies—have since eclipsed it in terms of overall cost. Like all medications Hemgenix does come with the risk of side effects. Patients administered the drug take regular liver function tests to ensure the vital organ is functioning correctly. This is because there is a risk the medication could trigger a potentially dangerous immune response. These tests are held one a week for the first three months before they are reduced to once a year. Patient information leaflets distributed with the drug also highlight a potential increased risk of cancer due to the fact it inserts itself into the DNA of cells. However, clinical studies have—so far—shown no cancers have been caused by Hemgenix use. Those taking Hemgenix must also use contraceptives like condoms for at least a year following treatment, due to a process called 'shedding'—where the drug can be passed through bodily fluids like semen. Patients are also forbidden from donating blood for this reason.
The Independent
an hour ago
- The Independent
Scandal-hit nursing regulator wrongly approved hundreds of nurses to work in UK, damning report reveals
A scandal-hit regulator wrongly approved more than 350 'fraudulent' or 'underqualified' nurses to work in the UK, amid a 'dysfunctional' culture exposed by The Independent. The Nursing and Midwifery Council (NMC), which regulates more than 800,000 nurses and midwives, is also failing to spot workers who could pose a serious risk to patient safety and to prioritise investigating them. These are just two of a series of failings uncovered in a review by the Professional Standards Authority (PSA), which regulates the NMC. That was prompted by The Independent 's exposé, which revealed that the organisation's 'toxic' culture had allowed nurses to work unchecked after whistleblower concerns were ignored. The PSA's report found that the NMC is failing to meet 7 of 18 national standards, and warned that: There are 'serious' cultural and operational issues within the NMC It is taking too long to deal with fitness-to-practice cases against nurses A small number of safeguarding failings could amount to a serious risk to the public Hundreds of fraudulent and underqualified nurses were placed on the register in error It had significant concerns about the NMC's ability to manage the quality of education provided by university training courses It has consistently failed for years to investigate cases against nurses fairly Have you been affected by this story? Email Alan Clamp, chief executive of the PSA, said its report showed that 'urgent and significant improvements are needed at the NMC'. The watchdog has escalated its concerns to health secretary Wes Streeting and to the vice-chair of the health and social care select committee. Responding to the report, Crystal Oldman – who is the chief executive of the Queen's Nursing Institute, which represents community nurses, and is also on a government-appointed board overseeing the NMC – said: 'A major step change is needed.' She warned: 'There's no evidence that there has been a wholesale change. If they've not met seven out of the 18 standards, then that is an enormous alarm bell to be ringing. 'Two years since the whistleblower 's concern, and there's no indication that they're succeeding on all of these counts, and that is hugely worrying for public protection. That's their first reason for being there: to protect the public.' Lynn Woolsey, chief nursing officer at the Royal College of Nursing, said the NMC needs to 'start turning the ship around for the good of nursing and healthcare', adding that 'urgent progress is needed' given the serious impact of its failings on some of its members. One key standard the NMC failed to meet is the requirement to ensure that its register of nurses and midwives is accurate. This came after the PSA found that more than 350 people had been added to it in error, allowing them to work as nurses in the UK. It said: 'The total number of people added to the register without meeting the NMC's requirements is over 350, and could be over 400, depending on the outcomes of the CBT and OET investigations. The NMC's register is so large that this amounts to a relatively small proportion, but we consider it a large number of individuals to be registered in error. 'Maintaining an accurate register is a key function and duty of a regulator, in the interests of public safety and public confidence. The NMC has added a large number of people to the register who had not met its requirements, and by the end of our review period it had not been able to fully remedy the situation.' These included 'fraudulent' applications from centres in India, Nigeria and Pakistan that test nurses against NMC requirements, such as being able to speak English to the required standard. The errors also included hundreds of newly qualified nurses who had not completed enough training hours, as revealed last year by The Independent. The NMC told The Independent that out of those investigated for fraudulent entries, 16 people were removed in relation to one centre in Pakistan and of the 30 registrants at a centre in Nigeria to face investigations, 19 were removed. For those in the India-based centre, 68 nurses were affected, and in all cases, it was found that there wasn't sufficient evidence to prove fraud. For nurses who may not have done the required hours, it was decided they met the competencies required for nursing standards. Another failing was the requirement to identify and prioritise all cases that pose a serious risk to patient safety and to seek interim orders, placing restrictions on staff under investigation, where appropriate. An internal audit carried out by the NMC, as revealed in January by this paper, found that it was failing to act on its safeguarding duties. While the PSA's review of 40 cases found no concerns in 90 per cent of them, it criticised the NMC for not seeking further information on criminal cautions and convictions accrued by a worker accused of domestic violence. The PSA warned: 'The NMC itself notes that it had been failing to identify and act on safeguarding concerns, and safeguarding continues to be the NMC's biggest strategic risk. This clearly raises concerns about the NMC's performance in this area over the course of the review period.' Paul Rees, the NMC's interim chief executive, said the report reflected a 'dark period' in the NMC's history. But he insisted 'radical change' was underway. He said: 'I recognise that our performance in 2023-2024 was not good enough, and since joining the NMC in January, I've committed to turning the organisation around – ensuring that we build a positive, empowering and inclusive culture for our people, and improve the regulatory experience for the public and nursing and midwifery professionals. 'Radical change is underway, and we have made significant strides through the delivery of our Culture Transformation and Fitness to Practice plans. In the coming days, we will publish ambitious equality and diversity targets to ensure we achieve equity for our colleagues and everyone involved in our processes.' The latest findings follow the publication last July of the findings of a review headed by barrister Nazir Afzal KC, which found evidence of a toxic and dysfunctional culture at 'every level' of the NMC, and that the organisation had turned a blind eye to serious sexual, physical and racist abuse. Shocking failures identified within Mr Afzal's report included a seven-year delay in striking off a nurse who was accused of raping a colleague and sexually assaulting a patient. A further review by Ijeoma Omambala KC, investigating the treatment of the whistleblower who first reported concerns to The Independent and the cases highlighted, was due to be completed last year but has been delayed.
